Barclays’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-235,648
| Closed | -$9.27M | – | 4806 |
|
|
2023
Q2 | $9.27M | Sell |
235,648
-482,022
| -67% | -$17M | 0.01% | 1018 |
|
|
2023
Q1 | $17.5M | Buy |
717,670
+483,518
| +206% | +$10.6M | 0.01% | 896 |
|
|
2022
Q4 | $5.01M | Sell |
234,152
-96,398
| -29% | -$2.06M | ﹤0.01% | 1631 |
|
|
2022
Q3 | $5.93M | Buy |
330,550
+316,278
| +2,216% | +$4.15M | 0.01% | 1065 |
|
|
2022
Q2 | $137K | Sell |
14,272
-371,367
| -96% | -$4.66M | ﹤0.01% | 3631 |
|
|
2022
Q1 | $6.49M | Buy |
385,639
+240,994
| +167% | +$3.56M | 0.01% | 1099 |
|
|
2021
Q4 | $2.42M | Buy |
144,645
+101,622
| +236% | +$1.67M | ﹤0.01% | 2254 |
|
|
2021
Q3 | $698K | Sell |
43,023
-43,370
| -50% | -$472K | ﹤0.01% | 2998 |
|
|
2021
Q2 | $544K | Buy |
86,393
+18,506
| +27% | +$119K | ﹤0.01% | 3037 |
|
|
2021
Q1 | $419K | Buy |
67,887
+1,331
| +2% | +$8.08K | ﹤0.01% | 3280 |
|
|
2020
Q4 | $460K | Buy |
66,556
+29,785
| +81% | +$191K | ﹤0.01% | 3288 |
|
|
2020
Q3 | $208K | Buy |
36,771
+11,905
| +48% | +$56.8K | ﹤0.01% | 3819 |
|
|
2020
Q2 | $127K | Buy |
+24,866
| New | +$104K | ﹤0.01% | 4361 |
|
|
2020
Q1 | – | Sell |
-1
| Closed | – | – | 6579 |
|
|
2019
Q4 | $0 | Buy |
+1
| New | +$4 | ﹤0.01% | 6965 |
|
|
2018
Q3 | – | Sell |
-4,000
| Closed | -$11K | – | 7487 |
|
|
2018
Q2 | $11K | Sell |
4,000
-19,885
| -83% | -$54.9K | ﹤0.01% | 6516 |
|
|
2018
Q1 | $65K | Sell |
23,885
-4,522
| -16% | -$13.1K | ﹤0.01% | 5692 |
|
|
2017
Q4 | $88K | Sell |
28,407
-27,569
| -49% | -$77.5K | ﹤0.01% | 5346 |
|
|
2017
Q3 | $158K | Sell |
55,976
-10,306
| -16% | -$27.8K | ﹤0.01% | 4610 |
|
|
2017
Q2 | $171K | Buy |
66,282
+53,219
| +407% | +$145K | ﹤0.01% | 4505 |
|
|
2017
Q1 | $47K | Sell |
13,063
-47,689
| -78% | -$202K | ﹤0.01% | 5381 |
|
|
2016
Q4 | $294K | Sell |
60,752
-12,679
| -17% | -$376K | ﹤0.01% | 3859 |
|
|
2016
Q3 | $3.39M | Buy |
73,431
+46,236
| +170% | +$2.61M | ﹤0.01% | 1584 |
|
|
2016
Q2 | $1.39M | Buy |
27,195
+23,844
| +712% | +$1.18M | ﹤0.01% | 2325 |
|
|
2016
Q1 | $141K | Buy |
3,351
+2,678
| +398% | +$136K | ﹤0.01% | 4111 |
|
|
2015
Q4 | $53K | Sell |
673
-8,779
| -93% | -$508K | ﹤0.01% | 4760 |
|
|
2015
Q3 | $378K | Sell |
9,452
-72,877
| -89% | -$3.86M | ﹤0.01% | 3598 |
|
|
2015
Q2 | $4.28M | Sell |
82,329
-11,980
| -13% | -$596K | ﹤0.01% | 1617 |
|
|
2015
Q1 | $4.34M | Sell |
94,309
-4,026
| -4% | -$209K | 0.01% | 1673 |
|
|
2014
Q4 | $4.33M | Sell |
98,335
-26,059
| -21% | -$1.09M | ﹤0.01% | 1829 |
|
|
2014
Q3 | $4.73M | Sell |
124,394
-7,828
| -6% | -$307K | ﹤0.01% | 1834 |
|
|
2014
Q2 | $5.55M | Buy |
132,222
+131,858
| +36,225% | +$4.84M | 0.01% | 1647 |
|
|
2014
Q1 | $13K | Sell |
364
-65,867
| -99% | -$2.22M | ﹤0.01% | 6815 |
|
|
2013
Q4 | $2.12M | Buy |
+66,231
| New | +$1.96M | ﹤0.01% | 2612 |
|
Barclays's ISEE Position: Q3 2023 in Review
Barclays sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2023, closing a stake of 235,648 shares — an estimated $9.27M sold.
Barclays first reported a position in ISEE in Q4 2013 and held it in 33 quarters. The position peaked at $17.5M in Q1 2023. 0 funds tracked by Wall St. Rank hold ISEE as of Q3 2023.
- Barclays reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Barclays sold 235,648 IVERIC bio, Inc. Common Stock shares in Q3 2023, an estimated $9.27M.
- Barclays first reported a position in IVERIC bio, Inc. Common Stock in Q4 2013 and held it in 33 quarters.
- Barclays's IVERIC bio, Inc. Common Stock position peaked at $17.5M in Q1 2023.
- 0 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2023.
Based on Barclays's 13F filing for Q3 2023, filed 7 Nov 2023.